Tag : VRON-0200

  • CONFERENCE UPDATE
    Novel therapeutic vaccine VRON-0200 shows promise for HBV functional cure

    ​Chronic hepatitis B virus (HBV) infection remains a significant global health challenge despite the availability of preventative vaccines. To address the unmet need for functional cure, immune-based treatments are gaining attention. VRON-0200, a therapeutic vaccine, has been developed to enhance and broaden T cell responses through the expression of HBV core and polymerase antigens fused with a genetically encoded checkpoint modifier (HSV-1 glycoprotein D). Interim data from an ongoing phase 1b trial was presented by Professor Wong, Lai-Hung Grace from The Chinese University of Hong Kong at the AASLD Annual Meeting 2024.

    Professor Wong, Lai-Hung Grace

    Professor, Department of Medicine and Therapeutics, Centre for Liver Health, Faculty of Medicine, The Chinese University of Hong Kong